Many important medications available today have been developed with public dollars and are costly to patients and other payers. Manufacturers justify these prices on the basis of the substantial research investment required to develop new drugs and conduct clinical trials demonstrating their utility and safety. But this rationale is more problematic when the government has funded a great deal of the seminal research leading to a particular product. Federal resources, primarily through the National Institutes of Health (NIH), have directly contributed to the discovery of some of the most transformative (and costly) medicines developed in the past 25 years, including imatinib (Gleevec), paclitaxel (Taxol), and erythropoetin alfa (Epogen).1
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.